The pioneer factor PBX1 is a novel driver of metastatic progression in ER'-positive breast cancer

Luca Magnani, Darren K. Patten, Van T M Nguyen, Sung Pil Hong, Jennifer H. Steel, Naina Patel, Ylenia Lombardo, Monica Faronato, Ana R. Gomes, Laura Woodley, Karen Page, David Guttery, Lindsay Primrose, Daniel Fernandez Garcia, Jacqui Shaw, Patrizia Viola, Andrew Green, Christopher Nolan, Ian O. Ellis, Emad A. Rakha & 5 others Sami Shousha, Eric W F Lam, B. Györffy, Mathieu Lupien, R. Charles Coombes

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Over 30% of ER' breast cancer patients develop relapses and progress to metastatic disease despite treatment with endocrine therapies. The pioneer factor PBX1 translates epigenetic cues and mediates estrogen induced ER' binding. Here we demonstrate that PBX1 plays a central role in regulating the ER' transcriptional response to epidermal growth factor (EGF) signaling. PBX1 regulates a subset of EGF-ER' genes highly expressed in aggressive breast tumours. Retrospective stratification of luminal patients using PBX1 protein levels in primary cancer further demonstrates that elevated PBX1 protein levels correlate with earlier metastatic progression. In agreement, PBX1 protein levels are significantly upregulated during metastatic progression in ER'-positive breast cancer patients. Finally we reveal that PBX1 upregulation in aggressive tumours is partly mediated by genomic amplification of the PBX1 locus. Correspondingly, ER'-positive breast cancer patients carrying PBX1 amplification are characterized by poor survival. Notably, we demonstrate that PBX1 amplification can be identified in tumor derived-circulating free DNA of ER'-positive metastatic patients. Metastatic patients with PBX1 amplification are also characterized by shorter relapse-free survival. Our data identifies PBX1 amplification as a functional hallmark of aggressive ER'-positive breast cancers. Mechanistically, PBX1 amplification impinges on several critical pathways associated with aggressive ER'-positive breast cancer.

Original languageEnglish
Pages (from-to)21878-21891
Number of pages14
JournalOncotarget
Volume6
Issue number26
Publication statusPublished - 2015

Fingerprint

Breast Neoplasms
Epidermal Growth Factor
Recurrence
Neoplasms
Proteins
Critical Pathways
Survival
Epigenomics
Cues
Estrogens
Up-Regulation
DNA
Therapeutics
Genes

Keywords

  • Breast cancer
  • Drug resistance
  • Estrogen receptor
  • Metastasis
  • Pioneer factors

ASJC Scopus subject areas

  • Oncology

Cite this

Magnani, L., Patten, D. K., Nguyen, V. T. M., Hong, S. P., Steel, J. H., Patel, N., ... Coombes, R. C. (2015). The pioneer factor PBX1 is a novel driver of metastatic progression in ER'-positive breast cancer. Oncotarget, 6(26), 21878-21891.

The pioneer factor PBX1 is a novel driver of metastatic progression in ER'-positive breast cancer. / Magnani, Luca; Patten, Darren K.; Nguyen, Van T M; Hong, Sung Pil; Steel, Jennifer H.; Patel, Naina; Lombardo, Ylenia; Faronato, Monica; Gomes, Ana R.; Woodley, Laura; Page, Karen; Guttery, David; Primrose, Lindsay; Garcia, Daniel Fernandez; Shaw, Jacqui; Viola, Patrizia; Green, Andrew; Nolan, Christopher; Ellis, Ian O.; Rakha, Emad A.; Shousha, Sami; Lam, Eric W F; Györffy, B.; Lupien, Mathieu; Coombes, R. Charles.

In: Oncotarget, Vol. 6, No. 26, 2015, p. 21878-21891.

Research output: Contribution to journalArticle

Magnani, L, Patten, DK, Nguyen, VTM, Hong, SP, Steel, JH, Patel, N, Lombardo, Y, Faronato, M, Gomes, AR, Woodley, L, Page, K, Guttery, D, Primrose, L, Garcia, DF, Shaw, J, Viola, P, Green, A, Nolan, C, Ellis, IO, Rakha, EA, Shousha, S, Lam, EWF, Györffy, B, Lupien, M & Coombes, RC 2015, 'The pioneer factor PBX1 is a novel driver of metastatic progression in ER'-positive breast cancer', Oncotarget, vol. 6, no. 26, pp. 21878-21891.
Magnani L, Patten DK, Nguyen VTM, Hong SP, Steel JH, Patel N et al. The pioneer factor PBX1 is a novel driver of metastatic progression in ER'-positive breast cancer. Oncotarget. 2015;6(26):21878-21891.
Magnani, Luca ; Patten, Darren K. ; Nguyen, Van T M ; Hong, Sung Pil ; Steel, Jennifer H. ; Patel, Naina ; Lombardo, Ylenia ; Faronato, Monica ; Gomes, Ana R. ; Woodley, Laura ; Page, Karen ; Guttery, David ; Primrose, Lindsay ; Garcia, Daniel Fernandez ; Shaw, Jacqui ; Viola, Patrizia ; Green, Andrew ; Nolan, Christopher ; Ellis, Ian O. ; Rakha, Emad A. ; Shousha, Sami ; Lam, Eric W F ; Györffy, B. ; Lupien, Mathieu ; Coombes, R. Charles. / The pioneer factor PBX1 is a novel driver of metastatic progression in ER'-positive breast cancer. In: Oncotarget. 2015 ; Vol. 6, No. 26. pp. 21878-21891.
@article{3188dbfe5e6542d8bdd510ff38ab97e1,
title = "The pioneer factor PBX1 is a novel driver of metastatic progression in ER'-positive breast cancer",
abstract = "Over 30{\%} of ER' breast cancer patients develop relapses and progress to metastatic disease despite treatment with endocrine therapies. The pioneer factor PBX1 translates epigenetic cues and mediates estrogen induced ER' binding. Here we demonstrate that PBX1 plays a central role in regulating the ER' transcriptional response to epidermal growth factor (EGF) signaling. PBX1 regulates a subset of EGF-ER' genes highly expressed in aggressive breast tumours. Retrospective stratification of luminal patients using PBX1 protein levels in primary cancer further demonstrates that elevated PBX1 protein levels correlate with earlier metastatic progression. In agreement, PBX1 protein levels are significantly upregulated during metastatic progression in ER'-positive breast cancer patients. Finally we reveal that PBX1 upregulation in aggressive tumours is partly mediated by genomic amplification of the PBX1 locus. Correspondingly, ER'-positive breast cancer patients carrying PBX1 amplification are characterized by poor survival. Notably, we demonstrate that PBX1 amplification can be identified in tumor derived-circulating free DNA of ER'-positive metastatic patients. Metastatic patients with PBX1 amplification are also characterized by shorter relapse-free survival. Our data identifies PBX1 amplification as a functional hallmark of aggressive ER'-positive breast cancers. Mechanistically, PBX1 amplification impinges on several critical pathways associated with aggressive ER'-positive breast cancer.",
keywords = "Breast cancer, Drug resistance, Estrogen receptor, Metastasis, Pioneer factors",
author = "Luca Magnani and Patten, {Darren K.} and Nguyen, {Van T M} and Hong, {Sung Pil} and Steel, {Jennifer H.} and Naina Patel and Ylenia Lombardo and Monica Faronato and Gomes, {Ana R.} and Laura Woodley and Karen Page and David Guttery and Lindsay Primrose and Garcia, {Daniel Fernandez} and Jacqui Shaw and Patrizia Viola and Andrew Green and Christopher Nolan and Ellis, {Ian O.} and Rakha, {Emad A.} and Sami Shousha and Lam, {Eric W F} and B. Gy{\"o}rffy and Mathieu Lupien and Coombes, {R. Charles}",
year = "2015",
language = "English",
volume = "6",
pages = "21878--21891",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

TY - JOUR

T1 - The pioneer factor PBX1 is a novel driver of metastatic progression in ER'-positive breast cancer

AU - Magnani, Luca

AU - Patten, Darren K.

AU - Nguyen, Van T M

AU - Hong, Sung Pil

AU - Steel, Jennifer H.

AU - Patel, Naina

AU - Lombardo, Ylenia

AU - Faronato, Monica

AU - Gomes, Ana R.

AU - Woodley, Laura

AU - Page, Karen

AU - Guttery, David

AU - Primrose, Lindsay

AU - Garcia, Daniel Fernandez

AU - Shaw, Jacqui

AU - Viola, Patrizia

AU - Green, Andrew

AU - Nolan, Christopher

AU - Ellis, Ian O.

AU - Rakha, Emad A.

AU - Shousha, Sami

AU - Lam, Eric W F

AU - Györffy, B.

AU - Lupien, Mathieu

AU - Coombes, R. Charles

PY - 2015

Y1 - 2015

N2 - Over 30% of ER' breast cancer patients develop relapses and progress to metastatic disease despite treatment with endocrine therapies. The pioneer factor PBX1 translates epigenetic cues and mediates estrogen induced ER' binding. Here we demonstrate that PBX1 plays a central role in regulating the ER' transcriptional response to epidermal growth factor (EGF) signaling. PBX1 regulates a subset of EGF-ER' genes highly expressed in aggressive breast tumours. Retrospective stratification of luminal patients using PBX1 protein levels in primary cancer further demonstrates that elevated PBX1 protein levels correlate with earlier metastatic progression. In agreement, PBX1 protein levels are significantly upregulated during metastatic progression in ER'-positive breast cancer patients. Finally we reveal that PBX1 upregulation in aggressive tumours is partly mediated by genomic amplification of the PBX1 locus. Correspondingly, ER'-positive breast cancer patients carrying PBX1 amplification are characterized by poor survival. Notably, we demonstrate that PBX1 amplification can be identified in tumor derived-circulating free DNA of ER'-positive metastatic patients. Metastatic patients with PBX1 amplification are also characterized by shorter relapse-free survival. Our data identifies PBX1 amplification as a functional hallmark of aggressive ER'-positive breast cancers. Mechanistically, PBX1 amplification impinges on several critical pathways associated with aggressive ER'-positive breast cancer.

AB - Over 30% of ER' breast cancer patients develop relapses and progress to metastatic disease despite treatment with endocrine therapies. The pioneer factor PBX1 translates epigenetic cues and mediates estrogen induced ER' binding. Here we demonstrate that PBX1 plays a central role in regulating the ER' transcriptional response to epidermal growth factor (EGF) signaling. PBX1 regulates a subset of EGF-ER' genes highly expressed in aggressive breast tumours. Retrospective stratification of luminal patients using PBX1 protein levels in primary cancer further demonstrates that elevated PBX1 protein levels correlate with earlier metastatic progression. In agreement, PBX1 protein levels are significantly upregulated during metastatic progression in ER'-positive breast cancer patients. Finally we reveal that PBX1 upregulation in aggressive tumours is partly mediated by genomic amplification of the PBX1 locus. Correspondingly, ER'-positive breast cancer patients carrying PBX1 amplification are characterized by poor survival. Notably, we demonstrate that PBX1 amplification can be identified in tumor derived-circulating free DNA of ER'-positive metastatic patients. Metastatic patients with PBX1 amplification are also characterized by shorter relapse-free survival. Our data identifies PBX1 amplification as a functional hallmark of aggressive ER'-positive breast cancers. Mechanistically, PBX1 amplification impinges on several critical pathways associated with aggressive ER'-positive breast cancer.

KW - Breast cancer

KW - Drug resistance

KW - Estrogen receptor

KW - Metastasis

KW - Pioneer factors

UR - http://www.scopus.com/inward/record.url?scp=84941215567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941215567&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 21878

EP - 21891

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -